Wellesley Pharmaceuticals

About:

Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated.

Website: https://wellesleypharma.com

Top Investors: Keiretsu Forum Northwest

Description:

Wellesley Pharmaceuticals ensures that the ability of Nocturol to reduce and sometimes eliminate nocturia symptoms can be disseminated. Wellesley Pharmaceuticals is in the development of an innovative, patented drug for treating Nocturia (frequent urination at night). Currently, there are no drugs on the market focused on nocturia and Wellesley plans to be first to market in the space. They believe that their proprietary drug, Paxerol, positions them to be the industry leader, addressing a massive unmet clinical need. Paxerol offers a significant advancement in terms of mechanism of action relative to existing indirect treatments of nocturia and should allow them to provide relief to hundreds of millions of people.